肝动脉栓塞化疗、聚乙二醇干扰素α2b和人参皂苷Rh2联合治疗HBV相关原发性肝癌临床研究

The efficacy of arterial chemotherapy, interferon and ginsenoside Rh2 combination in the treatment of hepatitis B-derived hepatoma

目的探讨肝动脉栓塞化疗(AC)、聚乙二醇干扰素α2b(PEGIFN)与人参皂苷Rh2(GRh1)联合治疗HBV相关原发性肝癌(HDP)的临床疗效及副作用。方法选择2011年3月至2012年2月期间在我院接受治疗的HDP患者163例,分别接受AC、PEGIFN和GRh1联合(A组),AC和PEGIFN联合(B组)以及AC和GRh1联合(C组)3种治疗方案,分析各自疗效及副作用。结果 A组患者中效率和显效率均显著高于B组和C组,而A组不良反应发生率均显著低于B组和C组。结论 AC、PEGINF和GRh12联合方案用于治疗HDP效果显著,且降低了化疗药物使用剂量和副作用。

This study was designed to evaluate the efficacy of arterial chemotherapy （AC）, PEG interferon a2b （PEGINF） and ginsenoside Rh2 （GRh2） combination in the treatment of hepatitis B-derived hepatoma （HDP） and analyze the side effects of the combination. Total 163 patients with hepatoma, who received AC, PEGINF and GRh2 combination （group A）, AC and PEGINF combination （group B） and AC or GRh2 combination （group C）, were divided into three groups. Statistical analyses were conducted for the marked, valid, invalid and deterioration in number of cases in three groups, as well as analysis of the occurrence of adverse reactions. Results showed that there were efficiency 82.14% and effective rate 57.14% in the group A, which were significantly higher than those of group B and C. Adverse reactions in group A, due to chemotherapy, were significantly lower than those in group B and group C. Results in this study suggested that the combined application of AC, PEGINF and GRh2 is an effective strategy for the treatment of HDP.